Media coverage about MacroGenics (NASDAQ:MGNX) has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MacroGenics earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.3577674504801 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news stories that may have impacted Accern’s analysis:

Several analysts recently commented on the company. Zacks Investment Research cut MacroGenics from a “hold” rating to a “sell” rating in a report on Wednesday, May 3rd. Morgan Stanley reduced their target price on MacroGenics from $24.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, May 8th. Cowen and Company reiterated a “buy” rating on shares of MacroGenics in a report on Friday, August 4th. ValuEngine cut MacroGenics from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Finally, BidaskClub cut MacroGenics from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $32.30.

Shares of MacroGenics (MGNX) traded up 2.59% during mid-day trading on Friday, reaching $16.24. The company had a trading volume of 125,238 shares. MacroGenics has a 12-month low of $14.36 and a 12-month high of $33.30. The firm’s market capitalization is $597.60 million. The stock has a 50 day moving average price of $17.36 and a 200 day moving average price of $18.72.

MacroGenics (NASDAQ:MGNX) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by $0.09. MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The business had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $15.82 million. During the same period last year, the firm posted $1.12 earnings per share. MacroGenics’s quarterly revenue was down 97.9% on a year-over-year basis. On average, equities analysts forecast that MacroGenics will post ($4.36) earnings per share for the current year.

In other news, SVP Jon Marc Wigginton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $20.00, for a total transaction of $100,000.00. Following the transaction, the senior vice president now directly owns 35,000 shares of the company’s stock, valued at $700,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 8.30% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “MacroGenics (NASDAQ:MGNX) Receives Daily Media Impact Rating of 0.03” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/13/macrogenics-nasdaqmgnx-receives-daily-media-impact-rating-of-0-03.html.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Insider Buying and Selling by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.